ArticleFrontiers in medicine2026
Elevated PTK6 expression is associated with tumor immune microenvironment remodeling and predicts poor prognosis in endometrial carcinoma.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Uterine corpus endometrial carcinoma (UCEC) incidence rises globally, with >50% of advanced/recurrent patients showing poor response to immune checkpoint inhibitors due to inadequate biomarkers. Protein tyrosine kinase 6 (PTK6), aberrantly expressed in malignancies and linked to tumor progression, lacks defined clinical significance in UCEC. Methods: Multi-omics analysis utilized UCEC RNA-seq (TCGA/GEO) and proteomics (CPTAC). PTK6 protein interactors from STRING were used for functional enrichment analysis. Tumor microenvironment (TME) was assessed via ESTIMATE (stromal/immune scores), TIMER3 (immune infiltration), and TCIA (immunophenoscore, IPS). Immunohistochemistry (IHC) validation ( Results: PTK6 was upregulated in UCEC ( Conclusion: PTK6 represents a context-dependent prognostic biomarker linked to tumor immune microenvironment remodeling in UCEC, suggesting its potential utility for immunotherapeutic optimization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.